NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On April 25, 2017, NuVasive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2017. A copy of this press release is furnished as Exhibit 99.1 to this Current Report.
Item 7.01 Regulation FD Disclosure.
During a conference call scheduled to be held at 1:30 p.m. Pacific Time on April 25, 2017, the Company’s Chairman and Chief Executive Officer, Chief Financial Officer, and President and Chief Operating Officer will discuss the Company’s results for the quarter ended March 31, 2017 and the Company’s outlook for the year ending December 31, 2017. The slide presentation for the conference call is furnished as Exhibit 99.2 to this Current Report.
The information contained in this Current Report and the Exhibits hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release issued by NuVasive, Inc. on April 25, 2017
99.2 Slide presentation
About NUVASIVE, INC. (NASDAQ:NUVA)
Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process. NUVASIVE, INC. (NASDAQ:NUVA) Recent Trading Information
NUVASIVE, INC. (NASDAQ:NUVA) closed its last trading session up +0.59 at 76.94 with 631,871 shares trading hands.